# CLN-619 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cln-619

> CLN-619, sponsored by Cullinan Therapeutics, Inc. (CGEM): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CLN-619 |
| Codes | CLN-619 |
| Sponsor | Cullinan Therapeutics, Inc. (CGEM) https://sec-api.dev/companies/cgem/catalysts |
| Indications | [relapsed/refractory multiple myeloma](https://sec-api.dev/indications/relapsed-refractory-multiple-myeloma) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Sep 2024: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: relapsed/refractory multiple myeloma.
- First seen 2025-02-27, last confirmed 2025-02-27.
- SEC Form 10-K (accession 0000950170-25-028346): "In September 2024, we dosed the first patient in the ongoing Phase 1 clinical trial to evaluate CLN-619 in patients with relapsed/refractory multiple myeloma." https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm

### Q2 2025: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-02-27, last confirmed 2025-02-27.
- SEC Form 10-K (accession 0000950170-25-028346): "Initial data from the disease specific expansion cohorts for endometrial and cervical cancers are anticipated in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cln-619.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CLN-619 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cln-619

```bibtex
@misc{secapidev_pdufa_cln_619_20261116,
  title        = {CLN-619 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cln-619}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cln_619_20261116","title":"CLN-619 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cln-619","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
